McKesson closes Apollo investment for minority interest in MMS
The transaction valued MMS at $13 billion and supports its planned separation into a publicly traded company.
See the latest news and media coverage for McKesson. We track all announcements, press releases, and industry mentions in real time, all in one place.
Diversified healthcare services and distribution company
mckesson.comLast updated
In short: McKesson reported strong fiscal 2026 results with $403.4B in revenue while advancing the multi-billion dollar spinoff of its medical-surgical unit.
The transaction valued MMS at $13 billion and supports its planned separation into a publicly traded company.
Revenues reached $96.3B in Q4 and $403.4B yearly. Adjusted EPS grew 16% in Q4 and 18% yearly. Fiscal 2027 guidance sets Adjusted EPS at $43.80-$44.60. Share repurchase program expanded.
Apollo will invest $1.25 billion for about a 13% stake, valuing MMS near $13 billion. McKesson retains majority ownership and operating control; deal subject to customary approvals.
It streamlines CGT delivery with Biologics by McKesson, offering direct therapy delivery, operational control, and value chain alignment.
McKesson reported strong fiscal Q4 and full-year 2026 results in May, and the stock continues to trade near record levels as investors digest earnings, guidance...
Earlier in June 2026, McKesson amended its credit agreement to add a US$2.25 billion senior secured...
McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier...
McKesson previously announced plans to separate its Medical-Surgical Solutions (MMS) business into an independent, publicly traded company.
Track McKesson and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to McKesson and other trending companies.